What is DayTwo?
Founded in 2015, DayTwo operates at the intersection of biotechnology and digital health. The company provides a sophisticated platform that delivers personalized nutrition insights, specifically designed to help users maintain target blood glucose levels. By utilizing proprietary algorithms derived from extensive research conducted at the Weizmann Institute of Science, DayTwo offers a unique value proposition: actionable, science-backed dietary recommendations tailored to an individual's unique microbiome and lifestyle. This approach positions the firm as a leader in the burgeoning field of precision medicine, moving beyond generic health advice toward highly individualized, data-centric interventions that address chronic metabolic conditions at their source.
How much funding has DayTwo raised?
DayTwo has raised a total of $85.4M across 6 funding rounds:
Series A
$12M
Series B
$31M
Other Financing Round
$5M
Debt
$150K
Debt
$254K
Unspecified
$37M
Series A (2017): $12M with participation from Seventure Partners and Johnson & Johnson
Series B (2019): $31M led by aMoon, Johnson & Johnson, Ofek Ventures, and Seventure Partners
Other Financing Round (2019): $5M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $254K backed by PPP
Unspecified (2021): $37M with participation from Micron Ventures, Poalim Capital Markets, and La’maison Fund
Key Investors in DayTwo
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on health, nutrition, and sustainable biotechnologies.
Johnson & Johnson
A global leader in healthcare, Johnson & Johnson invests in transformative medical technologies and consumer health solutions to improve patient outcomes worldwide.
Poalim Capital Markets
PCM provides comprehensive investment banking and advisory services, enabling corporations and institutional investors to access growth opportunities across global markets.
What's next for DayTwo?
With the support of its latest capital injection, DayTwo is well-positioned to scale its enterprise-level operations and expand its reach within the global digital health market. The company's strategic roadmap likely involves deepening its research capabilities and enhancing its digital infrastructure to support a broader user base. As the firm transitions from its initial development phase into a period of rapid commercial scaling, the focus will remain on integrating its metabolic insights into broader healthcare ecosystems. By leveraging its strong investor network, DayTwo aims to solidify its market position as a critical player in the future of preventative, technology-enabled healthcare, ultimately driving better patient outcomes through precision-based dietary management.
See full DayTwo company page
